Premium
Effectiveness of a New Calcium Antagonist in Severe Hypertension
Author(s) -
Burris James F.,
Santangelo Robert P.,
Mroczek William J.
Publication year - 1986
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1986.tb02955.x
Subject(s) - nitrendipine , medicine , hydrochlorothiazide , nifedipine , blood pressure , supine position , propranolol , antagonist , headaches , essential hypertension , anesthesia , pharmacology , calcium , surgery , receptor
Nitrendipine is a new nifedipine‐like calcium antagonist antihypertensive agent. In this study, nitrendipine 5–40 mg orally bid was administered for up to three months to 16 patients with severe essential hypertension (untreated supine diastolic blood pressure 115 mm Hg). Hydrochlorothiazide or propranolol or both were also given to patients who did not achieve goal blood pressure with nitrendipine alone. Five patients achieved goal blood pressure (supine 90 mm Hg) with nitrendipine alone and six more after the addition of a second drug, and only four required triple‐drug therapy. One patient was terminated from the study because of headaches, a common nitrendipine side effect. This study demonstrates that nitrendipine is an effective and well‐tolerated agent in the treatment of severe hypertension.